Economic [ocdi]
Efficiency [qnco]
Genetic screening [fndg]
Inform [aapp, imft, phsu]
abacavir [nnon, phsu]
Sulfate [inch]
treatment [ftcn]
HIV [virs]
Background [cnce]
Abacavir sulphate [nnon, phsu]
abacavir [nnon, phsu]
Associated [qlco]
Hypersensitivity reaction [patf]
Affect [menp]
Patients [podg]
Serious [qlco]
Complications [patf]
Rare [tmco]
Failure [ftcn]
abacavir [nnon, phsu]
re-challenge [idcn]
Following [tmco]
Hypersensitivity reaction [patf]
Fatal [qlco]
Genetic screening [fndg]
HLA-B [aapp, imft]
Patients [podg]
Likely [qlco]
experience [menp]
Hypersensitivity reaction [patf]
Incidence [qnco]
Reaction [ftcn]
Objective [inpr]
Assessed [acty]
Intrinsic [spco]
Value [qnco]
System, Health Care [hcro]
prospective [resa]
HLA-B [aapp, imft]
Screening [hlca]
Population [qnco]
Patients [podg]
Elevated [qlco]
risk factors [qnco]
Cardiovascular disease [dsyn]
Plasma [bdsu]
HIV [virs]
RNA [nnon]
copies/mL [qnco]
Pre-existing [qlco]
Renal insufficiency [dsyn]
Methods [inpr]
Two [qnco]
Approaches [spco]
To [qlco]
Evaluate [ftcn]
Costs [qnco]
Benefit [qnco]
prospective [resa]
Screening [hlca]
First [qnco]
Efficiency [qnco]
HLA-B [aapp, imft]
Screening [hlca]
Compared [acty]
Screening [hlca]
abacavir [nnon, phsu]
Initiation [menp]
Intrinsic [spco]
Value [qnco]
Screening [hlca]
Evaluated [ftcn]
Using [ftcn]
Tree, Decision [inpr]
Model [inpr]
Value [qnco]
Screening [hlca]
Assessed [acty]
Using [ftcn]
Discrete [qlco]
Event [evnt]
Simulation [resa]
Model [inpr]
Compared [acty]
HLA-B [aapp, imft]
Screening [hlca]
abacavir [nnon, phsu]
Initiation [menp]
Tenofovir [nnon, phsu]
Containing [ftcn]
Regimen [topp]
Screening [hlca]
Effectiveness [qlco]
Parameters [fndg]
Taken [cnce]
OPEN LABEL [resa]
Trial [resa]
Screening [hlca]
abacavir [nnon, phsu]
Initiation [menp]
Published [ocac]
studies [lbpr]
Treatment Efficacy [qlco]
Derived [qlco]
Clinical Trials [resa]
Modeling [inpr, resa]
Costs [qnco]
Values [qlco]
Parameters [fndg]
Derived [qlco]
Published [ocac]
sources [fndg]
Primary Data [idcn]
Analysis [lbpr]
Expert Opinion [cnce]
Multiple [qnco]
One [qnco]
Sensitivity [qnco]
scenario [ftcn]
Analysis [lbpr]
Performed [ftcn]
To [qlco]
Assess [acty]
Parameter [spco]
Uncertainty [idcn]
Primary Outcome Measure [inpr]
Short-term [tmco]
Screening [hlca]
Screening [hlca]
Analysis [lbpr]
Cost [qnco]
Long-term [tmco]
Analysis [lbpr]
Outcome [ftcn]
Presented [idcn]
qalys [tmco]
Costs [qnco]
effects [qlco]
discount [inpr]
Result [ftcn]
First [qnco]
days [tmco]
treatment [ftcn]
prospective [resa]
Screening [hlca]
abacavir [nnon, phsu]
Initiation [menp]
Cost [qnco]
Additional [ftcn]
hsr [resa]
Patients [podg]
PER [gngm]
Cost [qnco]
Screening [hlca]
Sensitive [ftcn]
Cost [qnco]
Genetic test [lbpr]
Hypersensitivity reaction [patf]
Costs [qnco]
Screening [hlca]
Performance [inbe]
Model [inpr]
Screening [hlca]
Informed [qlco]
abacavir [nnon, phsu]
More [ftcn]
effective [qlco]
Initiation [menp]
Tenofovir [nnon, phsu]
Containing [ftcn]
Regimen [topp]
base [inch]
Case [ftcn]
Sensitivity [qnco]
Analysis [lbpr]
Conclusions [idcn]
Result [ftcn]
Suggest [idcn]
prospective [resa]
HLA-B [aapp, imft]
Screening [hlca]
abacavir [nnon, phsu]
Initiation [menp]
Cost Savings [qnco]
Standard [qlco]
Component [mnob]
HIV [virs]
Care [acty]
